NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.58
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.87

24 Mar
2025

-0.150

OPEN

$5.05

-2.99%

HIGH

$5.05

671,806

LOW

$4.84

TARGET
$4.665 -4.2% downside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 4.3 6.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 35.2% 44.9% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 78.5 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx4.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx171.6 M
Book Value Per Share xxxxxxxxxxxxxxx60.1
Net Operating Cash Flow xxxxxxxxxxxxxxx22.8 M
Net Profit Margin xxxxxxxxxxxxxxx7.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx7.50 %
Return on Invested Capital xxxxxxxxxxxxxxx7.21 %
Return on Assets xxxxxxxxxxxxxxx5.54 %
Return on Equity xxxxxxxxxxxxxxx7.50 %
Return on Total Capital xxxxxxxxxxxxxxx4.58 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx20.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx6 M
Total Debt xxxxxxxxxxxxxxx9 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx130 M
Price To Book Value xxxxxxxxxxxxxxx4.97

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx2.5 M
Capex % of Sales xxxxxxxxxxxxxxx1.47 %
Cost of Goods Sold xxxxxxxxxxxxxxx44 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx119 M
Research & Development xxxxxxxxxxxxxxx30 M
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.4

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

24/02/2025

3

Neutral

$4.55

-6.57%

Citi notes Nanosonics' 1H25 results were in line with pre-announced figures, and management upgraded FY25 guidance on stronger-than-expected sales growth and a lower Australian dollar.

Trophon revenue grew by 18% in constant currency, with margins holding at 78.5%, reassuring the broker on its North American business fundamentals. The new Coris product remains under US FDA review and is expected to launch in Europe in 1Q26.

Operating expenses and working capital investment are set to increase to support the Coris launch, explain the analysts, with a US facility expansion expected to improve margins and hedge against potential tariffs.

Citi raises its FY25-27 EBIT forecasts by 36-41% and increases the target price to $4.55 from $3.40. Neutral maintained.

FORECAST
Citi forecasts a full year FY25 dividend of 0.00 cents and EPS of 6.20 cents.
Citi forecasts a full year FY26 dividend of 0.00 cents and EPS of 8.10 cents.

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

24/03/2025

1

Upgrade to Buy from Hold

$5.74

17.86%

Canaccord Genuity notes Nanosonics received de novo approval from the US FDA for the Coris system earlier than expected. This puts it in a good position to meet the initial launch timeline of 1Q26 and 70% of the total scope by volumes target within 12 months of approval.

The de novo approval will also help the company secure the 510K approval. No changes to forecasts.

Target price lifted to $5.74 from $4.47. The broker estimates the stock has an upside potential to $7.50 in a more bullish longer-term market share assumption scenario.

Rating upgraded to Buy from Hold.

FORECAST
Canaccord Genuity forecasts a full year FY25 EPS of 4.00 cents.
Canaccord Genuity forecasts a full year FY26 EPS of 4.00 cents.
Access Extra Coverage Research History >

NAN STOCK CHART

FNArena News on NAN

1
Australian Broker Call *Extra* Edition – Mar 24, 2025

Mar 24 2025 - Daily Market Reports
2
Next Week At A Glance 24-28 Mar 2025

Mar 21 2025 - Weekly Reports
3
In Brief: Top Picks In Financials, Retail & Healthcare

Mar 07 2025 - Weekly Reports
4
Rudi’s View: February’s Reality Check

Mar 05 2025 - Rudi's View
5
Australian Broker Call *Extra* Edition – Feb 25, 2025

Feb 25 2025 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
2
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
3
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
4
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
5
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
6
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
7
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
8
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
9
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
10
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps